Optimized Purification of Human Amyloid-beta (Aβ) 40 and Aβ42 Using an E. coli Expression System.

Area of Science:

• Biochemistry
• Neuroscience
• Molecular Biology

Background:

• Amyloid-beta (Aβ) peptides, specifically Aβ40 and Aβ42, are key components in the formation of amyloid plaques, a defining characteristic of Alzheimer's disease (AD).
• These peptides aggregate readily and exhibit neurotoxicity, making them central to AD pathogenesis.
• Accurate experimental investigation of Aβ aggregation and interactions necessitates pure, monomeric peptides with native sequences, free from modifications like N-terminal methionine.

Purpose of the Study:

• To establish an optimized protocol for producing recombinant human amyloid-beta 40 (Aβ40) and amyloid-beta 42 (Aβ42) peptides.
• To yield native-sequence, physiologically relevant Aβ monomers suitable for various experimental applications.
• To provide a reliable, cost-effective alternative to chemical synthesis for obtaining high-purity Aβ peptides.

Main Methods:

• Utilized a SUMO (Small Ubiquitin-like Modifier) fusion system for expressing Aβ40 and Aβ42 in Escherichia coli.
• Employed enzymatic cleavage to remove the SUMO tag, liberating native-sequence Aβ peptides.
• Purified the recombinant peptides to achieve high yield and purity.

Main Results:

• Successfully produced recombinant human Aβ40 and Aβ42 peptides with native sequences.
• Achieved high yield and purity of the monomeric Aβ peptides.
• The produced peptides closely mimic endogenous Aβ, validated by their suitability for aggregation and interaction studies.

Conclusions:

• The SUMO fusion system provides an efficient and cost-effective method for producing recombinant, native-sequence Aβ peptides.
• This protocol facilitates accurate Alzheimer's disease research by supplying reliable Aβ monomers for aggregation studies, structural analyses, and interaction assays.
• The availability of these high-quality recombinant peptides supports the development of improved models of AD pathogenesis and potential therapeutic strategies.